Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Sterling Pharmaceutical Services LLC
WARNING LETTER
•Sterling Pharmaceutical Services LLC•February 18, 2022

Sterling Pharmaceutical Services LLC – FDA Warning Letter, Feb 18, 2022

Record Details

On September 27, 2022, the FDA issued a Warning Letter to Sterling Pharmaceutical Services, LLC, following an inspection from February 7-18, 2022, at their Dupo, Illinois facility. The inspection revealed significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Failure to investigate discrepancies (21 CFR 211.192):** The firm, a contract manufacturer of sterile ophthalmic drugs, failed to adequately investigate repeated microbiological contamination in ISO 5 aseptic processing areas, including a sterility failure for one lot. Their "Restricted Access Barrier Systems" (RABS) lacked fundamental design elements like glove ports, permitting excessive operator intervention. Investigations were deemed inadequate, failing to address persistent adverse trends or consider design flaws. 2. **Inadequate environmental monitoring (21 CFR 211.42(c)(10)(iv)):** The environmental monitoring (EM) program, including personnel monitoring, was insufficient, with observed failures to monitor non-viable particulates and limited personnel monitoring. 3. **Failure to prevent microbiological contamination (21 CFR 211.113(b)):** The firm lacked adequate procedures to prevent contamination. Investigators observed poor aseptic behaviors, undocumented interventions,

Company
Sterling Pharmaceutical Services LLC
Inspection date
February 18, 2022
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations III
People
  • Jeffrey D. Meng (Associate Director)
  • Brian W. Garthwaite
View Company Profile

ID · 00588ea5-24d4-4e1b-8f1f-03f548dd6e68

Violation Codes10
21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.42(c)(10)(iv)21 CFR 211.113(b)21 U.S.C. 351(a)(2)(B)21 U.S.C. 35521 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 321(g)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Sterling Pharmaceutical Services LLC
  • 483 - 2024-05-01May 1, 2024
  • 483 - 2022-02-18February 18, 2022
  • 483 - 2021-05-14May 14, 2021
  • EIR - 2018-04-06April 6, 2018
  • 483 - 2018-04-06April 6, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sterling Pharmaceutical Services LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.